Age and follow-up time affect the prognostic value of the ECG and conventional cardiovascular risk factors for stroke in adult men
- Christina Ström Möller2,
- Jonas Häggström1,
- Björn Zethelius2,
- Bernice Wiberg3,
- Johan Sundström2,
- Lars Lind3
- 1AstraZeneca, Research and Development, Sodertalje, Sweden
- 2Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden
- 3Department of Medical Science, Uppsala University, Uppsala, Sweden
- Correspondence to: Dr C S Möller Department of Public Health and Caring Sciences, Section of Geriatrics, Uppsala Science Park, SE-751 85 Uppsala, Sweden; christina.strom_moller{at}pubcare.uu.se
- Accepted 30 October 2006
Abstract
Objectives: To explore whether the predictive power of mid-life ECG abnormalities and conventional cardiovascular risk factors for future stroke change over a 30-year follow-up period, and whether a repeated examination improves their predictive power.
Design and setting: Longitudinal population-based study.
Participants: 2322 men aged 50 years, with a follow-up period of 30 years. 1221 subjects were re-examined at age 70 years
Main outcome measure: Risk for fatal and non-fatal stroke during three decades of follow-up. Investigations included resting ECG and traditional cardiovascular risk factors.
Results: When measured at age 50 years, ST segment depression and T wave abnormalities, together with ECG-left ventricular hypertrophy, were of importance only during the first 20 years, but regained importance when re-measured at age 70 years. Blood pressure was a significant predictor for stroke over all three decades of follow-up. In elderly people only, there is evidence that apolipoprotein A1 may protect from future stroke.
Conclusion: Mid-life values for blood pressure and ECG abnormalities retain their predictive value over long follow-up periods even though they improved in predictive power when re-measured in elderly people. Despite lower prevalence, ECG abnormalities had greater impact at age 50 years than at age 70 years. By contrast, apolipoprotein A1 was protective for future stroke only at age 70 years.
- ApoA1, apolipoprotein A1
- apoB apolipoprotein B, CHD, coronary heart disease
- CVD, cardiovascular disease
- ECG-LVH, ECG-left ventricular hypertrophy
- HDL, high-density lipoprotein
- LDL, low-density lipoprotein
- SBP, systolic blood pressure
- TIA, transient ischaemic attack
- ULSAM, Uppasala Longitudinal Study of Adult Men
Footnotes
-
Funding: This work was funded by the Medical Faculty at Uppsala University, Royal Society of Science, Swedish Council for Planning and Co-ordination of Research, Swedish National Association against Heart and Lung Disease and the Swedish Medical Research Council. None of the funders had any role in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.
-
Competing interests: BZ, BW and JS have nothing to declare. During the time the study was conducted, CSM, JH and LL were also employed by AstraZeneca, Research and Development, Sweden but AstraZeneca has not had any role in the study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.
-
Contributions: All authors participated in the design of the study and helped to draft the manuscript. All authors read and approved the final manuscript. CSM performed the statistical analyses and JH provided statistical expertise.
Ethical approval: All subjects have given informed consent and the ethics committee of the Faculty of Medicine, Uppsala University, has approved the Uppsala Longitudinal Study of Adult Men.
